Frequency of Clopidogrel Resistance in Patients of Ischemic Heart Disease

10.5083/ejcm.20424884.93 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Syed Khizar Abbas Rizvi, Shahida Mohsin, Tahir Saeed, Saeed Ahmad, Shabbir Hussain, Muhammad Ikram Ullah


Clopidogrel and Aspirin are widely used antiplatelet agents in the prevention and treatment of ischemic heart disease (IHD). Many patients have been noticed with recurrence of major ischemic events, due to resistance of these drugs. Different platelet function tests can be used to evaluate the degree of achieved platelet inhibition in patients treated with clopidogrel. The objective of this study was to determine frequency of clopidogrel resistance in patients of ischemic heart disease. Seventy one patients of IHD were selected from out-patient department of Punjab Institute of Cardiology Lahore. Platelet aggregation studies were performed on Diamed Impact R. Clopidogrel response assay was performed with DiaAdin(ADP 110μmol/L). Chi-square test was applied to measure statistical significance. Resistance to Clopidogrel was observed in 17% (12 out of 71).

Clopidogrel resistance was significantly associated with female gender (p=0.046). In our study no statistically significant association was observed between clopidogrel resistance and risk factors like diabetes mellitus, family history ischemic heart disease, hypertension and smoking. We concluded that resistance to Clopidogrel therapy is seen in significant number of patients and female patients are at high risk of developing the resistance to clopidogrel therapy. These patients can be identified by performing platelet aggregation studies on Impact R.